Glenmark Pharmaceuticals Ltd. (GLENMARK): Glenmark Pharmaceuticals Share Price hits fresh 52-week high

Published: 27 August 2026 at 9:29 AM IST

Glenmark Pharmaceuticals Share Price is in focus after the stock rose to Rs 2,468, up 1.15% today, and touched a fresh 52-week high of Rs 2,483.30. The company’s market capitalisation stands at Rs 67,592.81 crore, placing GLENMARK among the notable names in the healthcare pack on NSE and BSE. Univest notes that the price event is verified by the day’s data, while the supplied information does not establish a company-specific catalyst for the move.

The session opened at Rs 2,440, matched the day’s low at Rs 2,440 and went on to mark the high at Rs 2,483.30 before settling at Rs 2,468. The day change of Rs 28 reflects the move against the previous close of Rs 2,440. For readers tracking Glenmark Pharmaceuticals Share Price Today, the event is relevant because the stock has now printed a fresh yearly high while also remaining within a clear market-cap and valuation discussion on Univest.

For investors searching Glenmark Pharmaceuticals Stock News, the immediate takeaway is factual: price moved higher, the fresh 52-week high was set, and the latest valuation metrics remain visible in the supplied data. Univest will continue to frame this as a price event first, then place the move in context through fundamentals, sector benchmarks and peer comparison. The numbers point to a stock that is drawing attention in the Indian stock market, but the supplied data alone does not identify a specific trigger.

Glenmark Pharmaceuticals Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,468
Previous Close	Rs 2,440
Today's Move	+Rs 28 (+1.15%)
Open	Rs 2,440
High	Rs 2,483.3
Low	Rs 2,440
Turnover	Rs 1.19 crore
Market Capitalisation	Rs 67,592.81 crore

Glenmark Pharmaceuticals Ltd. (GLENMARK) traded at Rs 2,468 versus the previous close of Rs 2,440, a rise of 1.15%. The stock opened at Rs 2,440, reached a high of Rs 2,483.3 and touched a low of Rs 2,440.

Glenmark Pharmaceuticals Share Price Today shows a straightforward upward move. The stock closed the prior session at Rs 2,440 and added Rs 28 to finish at Rs 2,468, a gain of 1.15%. It opened at Rs 2,440, traded between Rs 2,440 and Rs 2,483.30, and matched that upper end with the fresh 52-week high. Turnover stood at Rs 1.19 crore, which gives a factual sense of the day’s traded value without adding any interpretation beyond the supplied numbers.

The fresh 52-week high is important because it marks a yearly high for GLENMARK rather than an all-time high. On a simple arithmetic basis, the stock’s high of Rs 2,483.30 is above the previous close by Rs 43.30, or about 1.77%. That difference is useful for readers scanning Glenmark Pharmaceuticals Share Price Live and Glenmark Pharmaceuticals Share Price Update pages on Univest. The data confirms the day’s price event clearly, but it does not by itself explain a company-specific reason behind the move.

From a news perspective, Glenmark Pharmaceuticals Share News and Glenmark Pharmaceuticals Latest News searches are likely to focus on this fresh 52-week high because it is the day’s verified headline fact. For stock market today readers, the point is not to infer a narrative from the move, but to note that the stock printed a new one-year high while closing above the previous session’s level. That is the clearest factual summary available from the supplied data.

Glenmark Pharmaceuticals Ltd. (GLENMARK) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 67,592.81 crore
P/E Ratio	38.3x
P/B Ratio	6.28x
ROE	14.1%
ROCE	20.35%
EPS	Rs 63.7
Book Value Per Share	Rs 388.43
Dividend Yield	0.1%

Glenmark Pharmaceuticals Ltd. (GLENMARK) fundamental metrics show P/E 38.3x, P/B 6.28x, ROE 14.1%, ROCE 20.35%. These figures provide context only and are not a buy or sell signal.

Glenmark Pharmaceuticals Ltd. has a market capitalisation of Rs 67592.81 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 38.3x, P/B at 6.28x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 14.1% and ROCE of 20.35%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 63.7, book value per share of Rs 388.43, dividend yield of 0.1%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 30.54x, median ROE of 11.83%, median ROCE of 13.75%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	38.3x
Benchmark Median P/E	30.54x
Benchmark Average P/E	47.22x
Benchmark P/E Range	3.19x to 671.51x
Company P/B Ratio	6.28x
Benchmark Median P/B	2.76x
Company ROE	14.1%
Benchmark Median ROE	11.83%
Company ROCE	20.35%
Benchmark Median ROCE	13.75%
Company Market Capitalisation	Rs 67,592.81 crore
Benchmark Median Market Cap	Rs 623.8 crore

Glenmark Pharmaceuticals Ltd. (GLENMARK) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Glenmark Pharmaceuticals Ltd. (GLENMARK) has a P/E ratio of 38.3x, which is above the benchmark median of 30.54x, a difference of +25.41%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Glenmark Pharmaceuticals Ltd. (GLENMARK) has a ROE of 14.1%, which is above the benchmark median of 11.83%, a difference of +19.19%. Glenmark Pharmaceuticals Ltd. (GLENMARK) has a ROCE of 20.35%, which is above the benchmark median of 13.75%, a difference of +48%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Biocon Ltd.	BIOCON	67,567.12	137.34	2	1.35	3.26
Alkem Laboratories Ltd.	ALKEM	63,931.41	29.59	4.46	18.29	21.28
Abbott India Ltd.	ABBOTINDIA	56,173.06	34.88	10.88	34.67	46.72
Glaxosmithkline Pharmaceuticals Ltd.	GLAXO	50,483.85	48.02	20.35	48.76	66.79
Aurobindo Pharma Ltd.	AUROPHARMA	92,247.46	25.14	2.4	9.93	12.76

Glenmark Pharmaceuticals Ltd. (GLENMARK) has a P/E ratio of 38.3x compared with the displayed peer median of 34.88x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 14.1% compares with a peer median of 18.29% across the companies shown in the table. ROCE stood at 20.35% versus the displayed peer median of 21.28%, providing a capital-efficiency comparison. Glenmark Pharmaceuticals Ltd. (GLENMARK) has a market capitalisation of Rs 67,592.81 crore. Among the 5 peers shown, 1 has a larger market capitalisation.

Why Investors Are Watching Glenmark Pharmaceuticals

• Glenmark Pharmaceuticals Share Price hit a fresh 52-week high of Rs 2,483.30 and closed at Rs 2,468.
• The stock rose 1.15% today from the previous close of Rs 2,440.
• Market capitalisation stands at Rs 67,592.81 crore, with P/E at 38.3 and P/B at 6.28.
• ROE is 14.1% and ROCE is 20.35%, both above the same-industry benchmark median.
• Revenue for Jun-26 was Rs 40,184.83 crore and net profit was Rs 4,829.24 crore.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied data also places it within the same-industry comparison set used in this Glenmark Pharmaceuticals Stock Analysis. For readers following Glenmark Pharmaceuticals Share Price and Glenmark Pharmaceuticals Company News, this classification is the core business context available in the dataset.

The company’s reported financial indicators include revenue, net profit, EPS, book value and return ratios, which together give a basic company overview for Univest readers. That keeps Glenmark Pharmaceuticals Fundamental Analysis anchored to verified information rather than broad industry assumptions.

Track Glenmark Pharmaceuticals Share Price on Univest

Use Glenmark Pharmaceuticals Ltd. (GLENMARK) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Track Glenmark Pharmaceuticals Share Price on Univest for live share price updates, Glenmark Pharmaceuticals Share Price Today, sector context, valuation ratios, 52-week levels, shareholding pattern and company financials. Univest brings the key stock news, market cap and peer comparison together in one place for easier review.

Frequently Asked Questions

Why is Glenmark Pharmaceuticals Share Price in news today?

Ans. Glenmark Pharmaceuticals Share Price is in news because it touched a fresh 52-week high of Rs 2,483.30 and closed at Rs 2,468. The move also keeps the stock in focus for Glenmark Pharmaceuticals Stock News readers.

What is the current Glenmark Pharmaceuticals Share Price?

Ans. The current Glenmark Pharmaceuticals Share Price is Rs 2,468. It is up 1.15% from the previous close of Rs 2,440, with the session high matching the fresh 52-week high of Rs 2,483.30.

What is Glenmark Pharmaceuticals 52-week high?

Ans. Glenmark Pharmaceuticals 52-week high is Rs 2,483.30. The stock reached that level during the session, making it a fresh yearly high rather than an all-time high. The stock moved 1.15% during the session.

What is Glenmark Pharmaceuticals market capitalisation?

Ans. Glenmark Pharmaceuticals has a market capitalisation of Rs 67,592.81 crore. That places the company well above the same-industry median market cap shown in the supplied healthcare benchmark. The company operates in the Healthcare sector.

How does Glenmark Pharmaceuticals trade on valuation?

Ans. Glenmark Pharmaceuticals trades at a P/E of 38.3 and a P/B of 6.28. In the supplied industry benchmark, both sit above the median, while ROE and ROCE also stand above the benchmark median.

What do Glenmark Pharmaceuticals EPS and book value show?

Ans. Glenmark Pharmaceuticals reports EPS of 63.7 and book value of Rs 388.43. EPS reflects earnings per share, while book value shows accounting net worth per share, both useful in share price analysis.

How do Glenmark Pharmaceuticals ROE and ROCE compare?

Ans. Glenmark Pharmaceuticals reports ROE of 14.1% and ROCE of 20.35%. Both are above the same-industry benchmark median in the supplied data, which gives useful context for Glenmark Pharmaceuticals Stock Analysis.